Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...
The drug called lenacapavir is already sold under the brand name Sunlenca to treat HIV infections in the U.S., Canada, Europe ...
A deal that allows manufacturers to produce generic versions of lenacapavir has left out some Eastern European countries ...
A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...
A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...
In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is ...
Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
Tengrinews.kz - A revolutionary HIV drug has been created: clinical trials have shown that its twice-yearly injections are 96 ...
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
The twice-yearly HIV prevention shot developed by Gilead has shown impressive results in preventing infections among both men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback